Marc Goldschmidt, MD
Cardiovascular Disease · Stony Brook, NYNPI 1932109493
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $109,416 of the $148,035 with a category attached, or 73.9%. 35 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.4% of the total. Reporting peaked in 2024 at $29,393 and has fallen 53.0% since, to $13,813 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 572 payments — averaging $258.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$41K
- Pfizer$35K
- Merck$22K
- AstraZeneca$17K
- Abbott$11K
- Impulse Dynamics (USA) Inc.$8K
- plus $13K from 29 others
Across 10 payments — averaging $896.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$5K
- Novartis$4K
- Amgen$5
What the payments were for
- Consulting fees$15,98011%
- Speaking & faculty fees$109,41674%
- Travel & lodging$5,1934%
- Food & beverage$17,17812%
- Education$2670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 61 | $40,584 |
| Pfizer | 47 | $35,272 |
| Merck | 20 | $22,271 |
| AstraZeneca | 66 | $16,927 |
| Abbott | 86 | $11,351 |
| Impulse Dynamics (USA) Inc. | 13 | $8,432 |
| Novartis | 81 | $3,836 |
| Bridgebio Pharma, Inc. | 2 | $2,915 |
| Abiomed | 24 | $2,059 |
| Medtronic(2 entities) | 25 | $1,429 |
| Actelion Pharmaceuticals US, Inc. | 31 | $530 |
| Bristol Myers Squibb | 1 | $300 |
| Boehringer Ingelheim | 13 | $293 |
| Amgen | 13 | $215 |
| Akcea Therapeutics, Inc. | 15 | $213 |
| Endotronix, Inc. | 1 | $211 |
| Boston Scientific | 7 | $132 |
| Johnson & Johnson | 10 | $125 |
| Bayer | 9 | $124 |
| Vifor Pharma, Inc. | 8 | $120 |
| United Therapeutics Corporation | 7 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $98 |
| Amarin Pharma, Inc. | 6 | $88 |
| Bardy Diagnostics, Inc. | 4 | $57 |
| Gilead | 4 | $49 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Edwards Lifesciences | 1 | $43 |
| Scpharmaceuticals Inc. | 1 | $34 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $32 |
| Nuwellis, Inc. | 1 | $30 |
| Chiesi USA, Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Smith+Nephew | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$43,700
- CAMZYOS$34,572
- VYNDAQEL$31,548
- FARXIGA$14,050
- OPTIMIZER$9,204
- MitraClip System$4,500
- OPTIMIZER SMART SYSTEM$3,751
- Attruby$2,915
- ENTRESTO$2,650
- CARDIOMEMS$2,489
- Mitra Clip system$2,114
- Impella$1,283
- MitraClip$398
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$211
- HeartWare HVAD$136
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$135
- LOKELMA$125
- CardioMEMS HF System$123
- OPDIVO$122
How this compares
$148,035 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 22 | $786,273 |
| EntrestoSacubitril/Valsartan | 120 | $204,507 |
| JardianceEmpagliflozin | 157 | $187,067 |
| OpsumitMacitentan | 14 | $172,151 |
| EliquisApixaban | 37 | $55,205 |
| FarxigaDapagliflozin Propanediol | 36 | $54,940 |
| XareltoRivaroxaban | 37 | $51,393 |
| Torsemide | 141 | $2,496 |
| Ezetimibe | 77 | $2,075 |
| Metoprolol Succinate | 83 | $1,970 |
| Valsartan | 59 | $1,698 |
| Eplerenone | 18 | $1,358 |
| Carvedilol | 141 | $1,323 |
| Spironolactone | 121 | $921 |
| Levothyroxine Sodium | 14 | $918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $35,272 | $841,47859 claims |
| NovartisEntresto | $3,836 | $204,507120 claims |
| Boehringer IngelheimJardiance | $293 | $187,067157 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $530 | $172,15114 claims |
| AstraZenecaFarxiga | $16,927 | $54,94036 claims |
| Johnson & JohnsonXarelto | $125 | $51,39337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Stony Brook
- Szilard VorosStony Brook$3.7M
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.